Your Views on the Possible Provision of Zolgensma by NHS England, for Infants who have SMA Type 1
25 June 2019 / Posted in: Treatments & Research
Patient groups would like to find out what you think about this new treatment so that we can include your views in our submissions to the National Institute for Health and Care Excellence (NICE). Our survey closes on 21st July 2019.
Update re Nusinersen MAA
20 June 2019 / Posted in: Treatments & Research
We are so sorry to hear of the continued heightened distress in the SMA Community caused by NICE / NHS England’s decisions and communications to date. We are doing all we can to obtain a reply to the letter sent by clinicians and the patient groups on 14th June. This was sent following consultation, advice and a joint decision that this step was the most promising way to obtain a change to the MAA.
Children’s Hospice Week: 17th – 23rd June
14 June 2019 / Posted in: Information, Support
This is the only week in the year dedicated to raising awareness of children’s hospice and palliative care services across the UK, and those they support. This year’s theme is ‘Moments that Matter’.
Patient Advocacy Groups and Clinicians write to NICE & NHSE about the nusinersen MAA and the impact this has had on the SMA Community
14 June 2019 / Posted in: Treatments & Research
Today we have co-signed two letters to address the concerns that are being widely expressed about the nusinersen Managed Access Agreement (MAA).
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
11 June 2019 / Posted in: Treatments & Research
Scholar Rock announced that SRK-015 was well-tolerated in healthy volunteers across all tested doses and shows robust and durable target engagement, supporting evaluation in the Phase 2 trial in SMA, which is currently ongoing.
NICE Announces Appraisal of the Treatment Zolgensma for Infants with SMA Type 1
10 June 2019 / Posted in: Treatments & Research
Following an application by AveXis, NICE is progressing an appraisal of this treatment to see if it will recommend it for provision by NHS England for the treatment of infants with SMA Type 1. We will be asking the Community for their views and making a submission by the deadline of 31st July.
Access to Nusinersen in England Update
10 June 2019 / Posted in: Treatments & Research
We were extremely concerned to read some of the eligibility criteria in the draft MAA. We raised these concerns immediately with NICE, NHS England and Biogen. We continue to work with MDUK, Treat SMA and clinicians to establish the next most constructive steps at what is a most delicate stage in this long, difficult and distressing process. This needs very careful thought. We will communicate further on this as soon as possible this week.
'Give it Back' Campaign launched by DCP
03 June 2019 / Posted in: Information, Support
Today sees the launch of 'Give it Back' - a new campaign from the Disabled Children's Partnership to encourage the government to fill the £434million gap in social care funding for disabled children in England through the upcoming Spending Review.
NICE Releases Nusinersen Final Appraisal Determination (FAD), Draft MAA, and Committee Papers
03 June 2019 / Posted in: Treatments & Research
The FAD will form the guidance to the NHS and the committee papers summarise the information it considered in the process of getting to this stage. We note that the draft MAA still requires some further clarity and development. Jointly with MDUK and TreatSMA we have already raised concerns around this and NICE and NHS England have committed to respond to these at the earliest possible time.
SANDS Awareness Month - Finding Your Way
03 June 2019 / Posted in: Information, Support
June is SANDS awareness month. 2019's theme is ‘Finding Your Way’ after pregnancy and baby loss and seeking support in a way that is right for anyone needing it, with a particular focus on support for men and helping them find a way through grief. Find out more here including how to support the campaign.
